|
Acute lymphocytic leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.
|
31343482 |
2019 |
|
Eccrine porocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.
|
31145701 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here we report T-t-ALL with inv(11)(q21q23), which involves KMT2A and MAML2, a transcriptional coactivator of NOTCH proteins, that occurred after chemotherapy for Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.
|
31343482 |
2019 |
|
Mucoepidermoid Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CRTC1-MAML2 fusion in mucoepidermoid carcinoma of the breast.
|
30380176 |
2019 |
|
Eccrine Poroma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.
|
31145701 |
2019 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.
|
31343482 |
2019 |
|
Poroma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.
|
31145701 |
2019 |
|
Epithelial ovarian cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Variants in Notch signalling pathway genes, PSEN1 and MAML2, predict overall survival in Chinese patients with epithelial ovarian cancer.
|
30055028 |
2018 |
|
Pancreatic Adenosquamous Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CRTC1/3-MAML2 fusion gene and MAML2 gene rearrangement were not detected in any ASCs including Pan-MECs.
|
30138216 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Variants in Notch signalling pathway genes, PSEN1 and MAML2, predict overall survival in Chinese patients with epithelial ovarian cancer.
|
30055028 |
2018 |
|
Adenoid Cystic Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CRTC1/MAML2 and MYB/NFIB were also analyzed in MEC and adenoid cystic carcinoma cases, respectively.
|
28139061 |
2017 |
|
Adenoma, Sweat Gland
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conclude that CRTC1/3-MAML2 fusion gene analysis can be a useful method for diagnosing hidradenoma.
|
29079171 |
2017 |
|
Cerebrovascular accident
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Reduced expression of sGC, correlating with differential expression of MAML2, in stroke prone and spontaneously hypertensive rats was also seen, and RNA-Seq data demonstrated correlations between JAG1, NOTCH3, MAML2 and FRYL and the sGC subunits GUCY1A3 and GUCY1B3 in human coronary artery.
|
28465505 |
2017 |
|
Agenesis of corpus callosum
|
0.010 |
Biomarker
|
disease |
BEFREE |
CRTC1/MAML2 was present in 15 out of 17 evaluable MEC cases and MYB/NFIB was identified in the ACC case.
|
28139061 |
2017 |
|
Adenocarcinoma, Clear Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
Reevaluation of MAML2 fusion-negative mucoepidermoid carcinoma: a subgroup being actually hyalinizing clear cell carcinoma of the salivary gland with EWSR1 translocation.
|
27769871 |
2017 |
|
Aplasia Cutis Congenita
|
0.010 |
Biomarker
|
disease |
BEFREE |
CRTC1/MAML2 was present in 15 out of 17 evaluable MEC cases and MYB/NFIB was identified in the ACC case.
|
28139061 |
2017 |
|
Benign neoplasm of sweat gland
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conclude that CRTC1/3-MAML2 fusion gene analysis can be a useful method for diagnosing hidradenoma.
|
29079171 |
2017 |
|
Sarcoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we report the case of a KMT2A - MAML2 fusion discovered by Next-Generation Sequencing (NGS) analysis in front of an inv11 (q21q23) present in a 47-year-old female previously treated for a sarcoma in 2014, who had a B acute lymphoid leukemia (B ALL).
|
28535805 |
2017 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
One of its rare fusion partners, the mastermind like 2 (MAML2) gene has been reported in four cases of myeloid neoplasms after chemotherapy so far: two acute myeloid leukemias (AML) and two myelodysplasic syndrome (MDS), and two cases of secondary T-cell acute lymphoblastic leukemia (T-ALL).
|
28535805 |
2017 |
|
Multiple Chronic Conditions
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This multi-institutional study characterizes the clinicopathologic and molecular features of this tumor by utilizing next-generation sequencing to assess common mutations and gene fusions involved in thyroid carcinogenesis as well as fluorescence in-situ hybridization for MAML2 translocations typical of salivary gland mucoepidermoid carcinoma.
|
27910944 |
2017 |
|
Malignant neoplasm of soft tissue
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we report the case of a KMT2A - MAML2 fusion discovered by Next-Generation Sequencing (NGS) analysis in front of an inv11 (q21q23) present in a 47-year-old female previously treated for a sarcoma in 2014, who had a B acute lymphoid leukemia (B ALL).
|
28535805 |
2017 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma.
|
25953768 |
2015 |
|
Cutaneous Melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma.
|
25953768 |
2015 |
|
Carcinoma ex pleomorphic adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The CRTC1-MAML2 fusion oncoprotein was overexpressed in 2 mucoepidermoid Ca-ex-PAs.
|
24468654 |
2014 |
|
Pleomorphic adenoma of lacrimal gland
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To study genetic alterations in lacrimal gland pleomorphic adenoma (PA) and carcinoma ex pleomorphic adenoma (Ca-ex-PA) with focus on copy number changes and expression patterns of the translocation target genes PLAG1, HMGA2, and CRTC1-MAML2 in relation to clinical data.
|
24468654 |
2014 |